Effectiveness of erlotinib against recurrent pulmonary adenocarcinoma unresponsive to gefitinib: report of a case.
We report a case of recurrent pulmonary adenocarcinoma, found 2 years after resection, which responded extremely well to erlotinib, after gefitinib treatment had failed to evoke any response. This case report provides useful information for thoracic oncologists and shows that we should consider giving erlotinib after gefitinib for recurrent pulmonary adenocarcinoma, even if the gefitinib treatment is ineffective.
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, Japan.
Fumihiro
F
Shoji
Daigo
D
Kawano
Kensaku
K
Ito
Yosuke
Y
Morodomi
Tokujiro
T
Yano
Yoshihiko
Y
Maehara
D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D009364:Neoplasm Recurrence, Local; D011799:Quinazolines / Q000627:therapeutic use
D000970:Antineoplastic Agents; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib
N Engl J Med. 2005 Jul 14;353(2):123-32
16014882
Nat Clin Pract Oncol. 2006 Jan;3(1):50-7; quiz 1 p following 57
16407879
J Clin Oncol. 2003 Jun 15;21(12):2237-46
12748244
Lung Cancer. 2007 Dec;58(3):414-7
17618013
J Clin Oncol. 2005 Apr 10;23(11):2513-20
15738541
Oncologist. 2005 Aug;10(7):467-70
16079313
J Thorac Oncol. 2008 Apr;3(4):400-4
18379359
J Clin Oncol. 2007 Jun 20;25(18):2528-33
17577030
J Thorac Oncol. 2008 Apr;3(4):451-2
18379370
Eur J Surg Oncol. 2008 Jan;34(1):89-93
17449217